Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1730696 | 1.00 | SRC (0.47) | SRCPTPN1CTSSCTSKCTSL | |
| SCHEMBL1731564 | 0.93 | PTPN1 (0.52) | PTPN1CTSSCTSKPTPRAPTPN2 | |
| SCHEMBL1731562 | 0.93 | PTPN1 (0.52) | PTPN1CTSSCTSKPTPRAPTPN2 | |
| SCHEMBL2184299 | 0.93 | PTPN1 (0.52) | PTPN1CTSSCTSKPTPRAPTPN2 | |
| SCHEMBL1732540 | 0.90 | PTPN1 (0.42) | SRCPTPN1CTSSCTSKCTSL | |
| SCHEMBL1731839 | 0.90 | PTPN1 (0.42) | SRCPTPN1CTSSCTSKCTSL | |
| SCHEMBL1732781 | 0.88 | PTPN1 (0.43) | SRCPTPN1CTSSCTSKCTSL | |
| SCHEMBL1731804 | 0.88 | PTPN1 (0.43) | SRCPTPN1CTSSCTSKCTSL | |
| SCHEMBL5188845 | 0.88 | PTPN1 (0.43) | SRCPTPN1CTSSCTSKCTSL | |
| SCHEMBL1732891 | 0.86 | PTPN1 (0.50) | PTPN1PTPRAPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | claimed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | claimed |
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | SRC 251/4885PTPN1 10/4885CTSS 1794/4885 |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | SRC 149/4885PTPN1 9/4885CTSS 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.